Search results
Showing 1216 to 1230 of 1300 results for heart OR cardi* OR arrythmia
Digital technologies for multidisciplinary weight management
In development Reference number: GID-HTE10077 Expected publication date: TBC
Digital technologies to support smoking cessation in secondary care patients: early value assessment
In development Reference number: GID-HTE10061 Expected publication date: TBC
This advice has been updated and replaced by NICE healthtech guidance 562.
Urinary tract infection (recurrent): antimicrobial prescribing (NG112)
This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.
Polycystic ovary syndrome: metformin in women not planning pregnancy (ESUOM6)
Summary of the evidence on metformin for polycystic ovary syndrome (PCOS) in women not planning pregnancy to inform local NHS planning and decision-making
Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making
Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.
This indicator covers the percentage of patients on the CKD register and currently treated with an angiotensin receptor blocker (ARB) or an ACE inhibitor (unless these are contraindicated) who are also treated with an SGLT-2 inhibitor if they have: no type 2 diabetes and an eGFR 20 ml/min/1.73 m2 to 44 ml/min/1.73 m2, or no type 2 diabetes and an eGFR 45 ml/min/1.73 m2 to 59 ml/min/1.73 m2 and a urine albumin-to-creatinine ratio (ACR) of 22.6 mg/mmol or more, or type 2 diabetes and a urine ACR 3 mg/mmol or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Evidence summaries: new medicines – Integrated process statement (PMG11)
This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs
NICE has developed a medtech innovation briefing (MIB) on MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes
Alair bronchial thermoplasty system for adults with severe difficult to control asthma (MIB71)
NICE has developed a medtech innovation briefing (MIB) on the Alair bronchial thermoplasty system for adults with severe, difficult to control asthma
Evidence-based recommendations on melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver. This involves diverting the blood flow from the liver to the rest of the body while the drug is delivered directly into the liver.
View recommendations for IPG691Show all sections
Cardiovascular events (prevention, high risk) - anacetrapib [ID1164]
Discontinued Reference number: GID-TA11176
Discontinued Reference number: GID-TA10337
In development Reference number: GID-TA11482 Expected publication date: TBC